2025
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. Biomarker Research 2025, 13: 64. PMID: 40275414, PMCID: PMC12023351, DOI: 10.1186/s40364-025-00780-4.Peer-Reviewed Original ResearchLymphoma-specific survivalOverall survivalCAR-TRelative survivalChimeric antigen receptor T cellsDiffuse large B-cell lymphomaLarge B-cell lymphomaCumulative incidence of deathB-cell lymphomaPopulation-based cohort studyReceipt of chemotherapyIncidence of deathPeriod of diagnosisRefractory DLBCLB symptomsMultivariate survival modelsMedian ageT cellsImproved survivalCumulative incidenceSEER-17Disease courseCohort studyDisease stageFDA approval
2015
Interim analysis of hepatocellular carcinoma (HCC) screening and survival in 4,087 veterans diagnosed with HCC from 2008 to 2010.
Kaplan D, Taddei T, Aytaman A, Hunt K, Knott A, Dieperink E, Baytarian M, Fox R, Pedrosa M, D'Addeo K, Dai F, Mehta R, Duggal M, Pocha C, Skanderson M, Valderrama A. Interim analysis of hepatocellular carcinoma (HCC) screening and survival in 4,087 veterans diagnosed with HCC from 2008 to 2010. Journal Of Clinical Oncology 2015, 33: 243-243. DOI: 10.1200/jco.2015.33.3_suppl.243.Peer-Reviewed Original ResearchVeterans Health AdministrationHepatocellular carcinomaTumor sizeICD9 codesInterim analysisVA Corporate Data WarehouseCharlson-Deyo indexLiver disease careEtiology of cirrhosisPresence of ascitesLarger tumor sizeIVA/IVBHepatocellular carcinoma screeningTotal tumor sizeNumber of tumorsCorporate Data WarehouseMultivariate survival modelsMajority of veteransMedian OSAdvanced diseaseHepatitis CMilan criteriaBCLC stagingChart abstractionHepatitis B
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply